28 / 56
RESEARCH ARTICLE
SA JOURNAL OF DIABETES & VASCULAR DISEASE
26
VOLUME 13 NUMBER 1 • JULY 2016
10. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, Investigators.
Clinical characteristics and outcome of hospitalized patients with heart failure in
Japan.
Circ J
2006;
70
: 1617–1623.
11. Sliwa K, Davison BA, Mayosi BM, Damasceno A, Sani M, Ogah OS,
et al
.
Readmission and death after an acute heart failure event: Predictors and
outcomes in sub-Saharan Africa: Results from the THESUS-HF registry.
Eur Heart
J
2013;
34
: 3151–3159.
12. Scott I, Jackson C. Chronic heart failure management in Australia – time for
general practice centred models of care?
Austr Family Phys
2013;
42
: 343–346.
13. Scalvini S, Giordano A. Heart failure. Optimal postdischarge management of
chronic HF.
Nature Rev Cardiol
2013;
10
: 9–10.
14. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH,
et al
.
Investigators REiAHF. Serelaxin, recombinant human relaxin-2, for treatment of
acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial.
Lancet
2013;
381
: 29–39.
15. World Health Organisation–International Society of Hypertension guidelines for
the management of hypertension.Guideline subcommitee.
J Hypertens
1999;
17
: 151–183.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
method to estimate glomerular filtration rate from serum creatinine: A new
prediction equation. Modification of diet in renal disease study group.
Ann Int
Med
1999;
130
: 461–470.
17. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of
congestive heart failure: The Framingham study.
New Engl J Med
1971;
285
:
1441–1446.
18. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-
Wilson PA,
et al
. ESC guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008: The task force for the diagnosis and treatment of
acute and chronic heart failure 2008 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association of the ESC (HFA)
and endorsed by the European Society of Intensive Care Medicine (ESICM).
Eur J
Heart Failure
2008;
10
: 933–989.
19. Ogah OS, Adebanjo AT, Otukoya AS, Jagusa TJ. Echocardiography in Nigeria:
Use, problems, reproducibility and potentials.
Cardiovasc Ultrasound
2006;
4
:
13.
20. Devereux RB, Reichek N. Echocardiographic determination of left ventricular
mass in man. Anatomic validation of the method.
Circulation
1977;
55
: 613–
618.
21. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid
atherosclerosis and left ventricular hypertrophy.
J Am Coll Cardiol
1995;
25
:
83–90.
22. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health
and disease: Doppler echocardiography is the clinician's rosetta stone.
J Am Coll
Cardiol
1997;
30
: 8–18.
23. Rits IA. Declaration of Helsinki. Recommendations guidings doctors in clinical
research.
World Med J
1964;
11
: 281.
24. Ogah OS, Stewart S, Falase AO, Akinyemi JO, Adegbite GD, Alabi AA,
et al
.
Contemporary profile of acute heart failure in southern Nigeria: Data from the
Abeokuta heart failure clinical registry.
JAAC Heart Failure
2014;
2
(3): 250–259.
25. Oyoo GO, Ogola EN. Clinical and socio-demographic aspects of congestive
heart failure patients at Kenyatta National Hospital, Nairobi.
East African Med J
1999;
76
: 23–27.
26. Adams KF, Jr, Uddin N, Patterson JH. Clinical predictors of in-hospital mortality
in acutely decompensated heart failure-piecing together the outcome puzzle.
Congest Heart Failure
2008;
14
: 127–134
27. Okin PM, Roman MJ, Devereux RB, Kligfield P. Association of carotid
atherosclerosis with electrocardiographic myocardial ischemia and left
ventricular hypertrophy.
Hypertension
1996;
28
: 3–7.
28. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V,
Sutton GC. Incidence and aetiology of heart failure; a population-based study.
Eur Heart J
1999;
20
: 421–428.
29. Arena R, Lavie CJ. The obesity paradox and outcome in heart failure: Is excess
bodyweight truly protective?
Future Cardiol
2010;
6
: 1–6.
30. Ballo P, Betti I, Barchielli A, Castelli G, Luca LD, Gheorghiade M, Zuppiroli
A. Body mass index, gender, and clinical outcome among hypertensive
and diabetic patients with stage a/b heart failure.
Obesity
2013;
21
(9): E500–507.
31. Komukai K, Minai K, Arase S, Ogawa T, Nakane T, Nagoshi T,
et al
. Impact of
body mass index on clinical outcome in patients hospitalized with congestive
heart failure.
Circ J
2012;
76
: 145–151.
32. Senni M, Parrella P, De Maria R, Cottini C, Bohm M, Ponikowski P,
et al
.
Predicting heart failure outcome from cardiac and comorbid conditions: The
3C-HF score.
Int J Cardiol
2013;
163
: 206–211.
33. Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ,
investigators. Both in- and out-hospital worsening of renal function predict
outcome in patients with heart failure: Results from the CoOrdinating study
evaluating outcome of Advising and Counseling in Heart failure (COACH).
Eur
J Heart Failure
2009;
11
: 847–854.
34. Ghali JK, Wikstrand J, van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson
A,
et al
, Group M-HS. The influence of renal function on clinical outcome and
response to beta-blockade in systolic heart failure: Insights from metoprolol
CR/XL randomized intervention trial in chronic HF (MERIT-HF).
J Cardiac Failure
2009;
15
: 310–318.
35. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S,
et al
.
Candesartan in heart failure: Assessment of reduction in morbidity I. Renal
function as a predictor of outcome in a broad spectrum of patients with heart
failure.
Circulation
2006;
113
: 671–678.
36. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and
the risk of stroke and death. The framingham heart study.
Circulation
. 1995;
92
: 835–841.
37. Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter
MM,
et al
. Heart Failure Clinical Research N. Phosphdiesterase-5 inhibition to
improve clinical status and exercise capacity in diastolic heart failure (RELAX)
trial: Rationale and design.
Circulation Heart Failure
2012;
5
: 653–659.
38. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Poole JE, Lee KL, Bardy GH,
Investigators SC-H. Outcome in African Americans and other minorities in the
Sudden Cardiac Death in HEart Failure Trial (SCD-HEFT).
Am Heart J
2008; B:
501–506.
39. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized Early versus
Late AbciXimab in Acute Myocardial Infarction treated with primary coronary
intervention (RELAX-AMI trial).
J Am Coll Cardiol
2007;
49
: 1517–1524.
40. Ouriel K, Castaneda F, McNamara T, Swischuk J, Tepe G, Smith JJ,
et al
. Reteplase
monotherapy and reteplase/abciximab combination therapy in peripheral
arterial occlusive disease: Results from the RELAX trial.
J Vasc Interven Radiol
2004;
15
: 229–238.
41. Adlam D, Silcocks P, Sparrow N. Using BNP to develop a risk score for heart
failure in primary care.
Eur Heart J
2005;
26
: 1086–1093.
42. Sliwa K, Davison BA, Mayosi BM, Damasceno A, Sani M, Ogah OS,
et al
.
Readmission and death after an acute heart failure event: Predictors and
outcomes in sub-Saharan Africa: Results from the THESUS-HF registry.
Eur Heart
J
2013;
34
(40): 3151–3159.